Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA | BSE: 543635) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.
This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products.
PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.
PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area.
Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
At Piramal Pharma Solution, we are dedicated to creating a positive impact on the well-being of our patients and consumers through the delivery of exceptional products and services. We strive to serve not only our patients and customers but also our broader community, employees, partners, stakeholders, and the environment. Our commitment is reflected in the embodiment of our values, evident in both personal and corporate actions, decisions, and conduct in our daily operations.
Chairperson, Piramal Pharma Ltd.
The values that guide our culture are embodied in our purpose - ‘Doing Well and Doing Good’. We believe that individual success and organisational growth cannot be mutually exclusive from responsible and ethical business practices. Our purpose provides clear guidance to our people and ensures that we identify the right partners to create mutual, enduring value.
Expertise - Strive for deeper understanding of our domain
Innovation - We aspire to do things creatively
Entrepreneurship - We are empowered to act decisively and create value
Integrity - We are consistent in our thought, speech and action
Trusteeship - We protect and enhance the interests of our customers, community, employees, partners and shareholders
Humility - We aspire to be the best, yet strive to be humble
Performance - We strive to achieve market leadership in scale and profitability, wherever we compete.
Resilience - We aspire to build businesses that anticipate, adapt and endure for generations.
